Novartis names chairman-designate of soon to be spun out Sandoz

Swiss pharma giant Novartis’s (NOVN: VX) board of directors announced today the appointment of Gilbert Ghostine as chairman-designate of the new board of Sandoz, its biosimilars and generics business.

Mr Ghostine has served as chief executive of Geneva, Switzerland-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.

Mr Ghostine will become chairman of the new board of directors of Sandoz, which – as Novartis has previously indicated - will be formed following the spin-off from Novartis in the second half of 2023, subject to final Novartis board and shareholder approvals.